Last reviewed · How we verify
Placebo for Enzalutamide
A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect.
A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect. Used for Control arm in clinical trials for enzalutamide-treated conditions (e.g., castration-resistant prostate cancer).
At a glance
| Generic name | Placebo for Enzalutamide |
|---|---|
| Sponsor | Pfizer |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Placebos are inert substances used as controls in clinical trials to establish the efficacy of an active drug by comparison. Any observed effects in placebo recipients are attributed to the placebo effect—psychological and physiological responses to the expectation of treatment rather than to a specific molecular mechanism. In this case, the placebo is used as a comparator in trials evaluating enzalutamide, an androgen receptor antagonist.
Approved indications
- Control arm in clinical trials for enzalutamide-treated conditions (e.g., castration-resistant prostate cancer)
Common side effects
Key clinical trials
- Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991) (PHASE3)
- A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer (PHASE2)
- Contributions to Hypertension With Androgen Deprivation Therapy (PHASE4)
- An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) (PHASE3)
- A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy (PHASE3)
- Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy (PHASE2)
- A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) (PHASE3)
- An Asian Study to Evaluate Efficacy and Safety of Oral Enzalutamide in Progressive Metastatic Prostate Cancer Participants (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo for Enzalutamide CI brief — competitive landscape report
- Placebo for Enzalutamide updates RSS · CI watch RSS
- Pfizer portfolio CI